Request a Call

Request a Call from a

Information for:


Click here if you are a healthcare professional and would like more information on Pradaxa® (dabigatran etexilate)

Information intended for:


Click here for more information on Pradaxa®

PC-GB -101423 V1 January 2021

(dabigatran etexilate)
for the prevention
of stroke in patients with NVAF

Pradaxa® (dabigatran etexilate) is a direct thrombin inhibitor indicated for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors for stroke.1,2 Recommended by national guidelines, Pradaxa® is available for you to prescribe today.3-5

Pradaxa® is recommended nationally
and available locally

The NICE clinical guidelines on the management of atrial fibrillation recommend Pradaxa® as an option for the prevention of stroke and systemic embolism within its licensed indication. Pradaxa® is also accepted for use within NHS Scotland for this indication, as per its SMC approval.3-5

Pradaxa® is available for you to prescribe locally, with over 33,000 NVAF patients in the UK benefitting from Pradaxa® each year.3-6

Pradaxa® is the NOAC with the lowest daily cost7

Savings of


Per patient per year vs Apixaban

Savings of


Per patient per year vs Rivaroxaban

Savings of


Per patient per year vs Edoxaban

At only £1.70 per day, Pradaxa® has the lowest daily cost of all the currently available NOACs based on the NHS list price, with potential cost savings of up to £73 per patient per year.7

Prices based on NHS list price.

Annual savings per patient calculated by multiplying the difference in the daily price of each drug relative to Pradaxa® by 365. The total savings are calculated by multiplying the savings per patient on apixaban, rivaroxaban and edoxaban by the number of patients receiving them, respectively.

Pradaxa® 110mg is a low-dose NOAC
with a high standard of evidence

Over 6,000 patients

Pradaxa® 110mg has been prospectively tested in a randomised clinical trial with over 6,000 patients with NVAF1-3

Pradaxa® 110 mg b.d. has a proven efficacy and safety profile1-3

Prevention of stroke and systemic embolism

Pradaxa® 110 mg b.d. was non-inferior to warfarin for the prevention of stroke and systemic embolism1-3

Stroke or systemic embolism was the primary outcome

Reduced risk of major bleeding, intracranial bleeding and total bleeding

Pradaxa® 110 mg b.d. significantly reduced the risk of major bleeding, intracranial bleeding and total bleeding vs warfarin1-3

Major bleeding was the primary safety outcome

Simple, physician-directed dosing

Pradaxa® is available in doses of 110mg b.d. and 150mg b.d. This allows you the flexibility to select the most appropriate dose for your patient, offering you the choice of prescribing the lower dose if you are concerned your patient may have an increased risk of bleeding.*1,2,11

Renal function should be assessed by calculating the creatinine clearance (CrCL) prior to initiation of treatment. Pradaxa® is contraindicated in patients with severe renal impairment (i.e. CrCL <30mL/min). Prior to prescribing Pradaxa® please ensure that you have assessed the patient's risk of stroke, risk of bleeding and their renal function. These will help you determine the patient's suitability for Pradaxa® and the appropriate dose for them.1,2

Selecting the correct Pradaxa® (dabigatran etexilate) dose for your NVAF patients
Selecting the correct Pradaxa® dose for your NVAF patients

*Examples of increased bleeding risk may include: the patient is 75–80 years old; suffering from gastritis, oesophagitis or gastroesophageal reflux; has moderate renal impairment (CrCL 30–50mL/min). For further details of factors which may increase the bleeding risk please refer to the Summary of Product Characteristics.1,2

Specific reversal agent,

Life happens. But with Pradaxa®, you and your patients have the reassurance that Praxbind® can provide immediate, complete and sustained reversal of the anticoagulant effects of Pradaxa® in case of emergency surgery/urgent procedures or life-threatening or uncontrolled bleeding.12-14

Emergency Surgery/ Urgent procedures – Life-threatening or uncontrolled bleeding
Emergency Surgery/ Urgent procedures – Life-threatening or uncontrolled bleeding
Pradaxa® (dabigatran etexilate) Reversibility: Complete/Immediate/Sustained
Pradaxa® (dabigatran etexilate) Reversibility: Complete/Immediate/Sustained
Widely Available Across the UK and Ireland
Widely Available Across the UK and Ireland

Do your patients ask about reversal?

NICE notes that one of the top 10 questions patients ask their doctor when discussing oral anticoagulants as a treatment option to reduce their risk of stroke is: What happens if the effects need to be reversed in an emergency (for example, after an injury or before emergency surgery)?

Thanks to Praxbind®, you can offer your patients the reassurance of immediate, complete and sustained reversal of Pradaxa® in an emergency.12

Support your NVAF patients
treated with Pradaxa®

A range of materials are available to support your patients with non-valvular AF being treated with Pradaxa® for stroke prevention, which may aid their treatment adherence.

Pradaxa® (dabigatran etexilate) patient alert card

Pradaxa® patient alert card

  • For the patient to keep with them at all times; one card contained within each pack of Pradaxa®
  • Informs healthcare professionals that the patient is receiving anticoagulation therapy with Pradaxa®
Pradaxa® (dabigatran etexilate) patient support booklet (SPAF)

Pradaxa® patient support booklet (SPAF)

  • Provides patients with detailed information on why they’ve been prescribed Pradaxa®, how to take their treatment and when they should seek medical advice
Pradaxa® (dabigatran etexilate) patient starter card (SPAF)

Pradaxa® patient starter card (SPAF)

  • Provides patients with a quick reference guide to taking Pradaxa®

NVAF — non-valvular atrial fibrillation

NICE — National Institute for Health and Care Excellence

NOAC — non-Vitamin K antagonist oral anticoagulant

SMC — Scottish Medical Consortium

  1. Pradaxa® 110mg hard capsules Summary of Product Characteristics
  2. Pradaxa® 150mg hard capsules Summary of Product Characteristics
  3. NICE Clinical Guideline (CG180): Atrial fibrillation: management. Published June 2014
  4. SMC Advice (672/11). Dabigatran etexilate 110mg and 150mg hard capsules (Pradaxa®). Published August 2011
  5. NICE Technology Appraisal Guidance (TA249). Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. Published March 2012 
  6. Boehringer Ingelheim. Data on File. DBG 19-05
  7. (accessed August 2020)
  8. Connolly SJ, et al. N Engl J Med 2009;361(12):1139–1151
  9. Connolly SJ, et al. N Engl J Med 2010;363(19):1875–1876
  10. Connolly SJ, et al. N Engl J Med 2014;371(15): 1464–1465
  11. Rubboli A. Eur J Intern Med 2019;62:e11-e12 
  12. Praxbind® Summary of Product Characteristics
  13. Pollack CV, et al. N Engl J Med 2017;377(5):431-411)
  14. Schiele F, et al. Blood 2013; 121(18):3554-3562
  15. RCEM and NPIS Guideline on Antidote Availability for Emergency Departments, January 2017 
PC-GB-100765 V2 | January 2021


You are about to leave the Boehringer Ingelheim site for a site not created, managed or maintained by Boehringer Ingelheim.

Boehringer Ingelheim hopes that this link will be of interest and use to visitors, but it accepts no liability in relation to the website or its contents and gives no warranty as to the accuracy or completeness of information, data or reports on the website, to the fullest extent that any such liability may be lawfully excluded. Nor does Boehringer Ingelheim necessarily endorse or support any content on the third party website or any further links from their website.